Evidence map›Paper›PMID 39431021›Full record

ArticleTheranostics2024

Highly potent and selective PPARδ agonist reverses memory deficits in mouse models of Alzheimer's disease.

Hyeon Jeong Kim, Haelee Kim, Jaeyoung Song, Jun Young Hong, Elijah Hwejin Lee, Ashwini M Londhe, Ji Won Choi, Sun Jun Park, Eunseok Oh, Heeseok Yoon and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Hyeon Jeong KimCenter for Brain Disorders, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
Haelee KimNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Jaeyoung SongNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Jun Young HongLaboratory of Marine Drugs, School of Earth and Environmental Sciences, Seoul National University, NS-80 Seoul 08826, Republic of Korea.
Elijah Hwejin LeeCenter for Brain Disorders, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
Ashwini M LondheCenter for Brain Disorders, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
Ji Won ChoiCenter for Brain Disorders, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
Sun Jun ParkCureverse, lnc., H2 building, KIST, Seoul 02792, Republic of Korea.
Eunseok OhLaboratory of Marine Drugs, School of Earth and Environmental Sciences, Seoul National University, NS-80 Seoul 08826, Republic of Korea.
Heeseok YoonNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Hoosang HwangLaboratory of Marine Drugs, School of Earth and Environmental Sciences, Seoul National University, NS-80 Seoul 08826, Republic of Korea.
Dongyup HahnLaboratory of Marine Drugs, School of Earth and Environmental Sciences, Seoul National University, NS-80 Seoul 08826, Republic of Korea.
Kyungjin JungNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Sugyeong KwonNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Tara Man KadayatNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Min Jung MaNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Jeongmin JooNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Jina KimNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Jae Hyun BaeNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Hayoung HwangNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Ae Nim PaeCenter for Brain Disorders, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
Sung Jin ChoCureverse, lnc., H2 building, KIST, Seoul 02792, Republic of Korea.
Jong-Hyun ParkCenter for Brain Disorders, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
Jungwook ChinNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Heonjoong KangLaboratory of Marine Drugs, School of Earth and Environmental Sciences, Seoul National University, NS-80 Seoul 08826, Republic of Korea.
Ki Duk ParkCenter for Brain Disorders, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseDisease Models, AnimalMemory DisordersPPAR deltaAnimalsHumansMaleMiceMice, Inbred C57BLMice, TransgenicMicrogliaNeuroinflammatory DiseasesPPAR deltaAlzheimer's diseaseanti-inflammationBACE1glial activationPPARδ agonist

Identifiers

PMID39431021
PMCPMC11488110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.